
EBV EBNA4 243-253, RRARSLSAERY
Description
About EBV EBNA4 243-253, RRARSLSAERY
The Epstein-Barr Virus (EBV) (strain AG876) Epstein-Barr nuclear antigen (EBNA) 4 Peptide (IEDB: 55529) is a high quality epitope peptide for stimulation of antigen-specific T cells in T cell assays such as ELISPOT, ICS, cytotoxicity or proliferation assays. The Epstein-Barr nuclear antigen (EBNA) Peptide, H-RRARSLSAERY-OH (Uniprot: Q1HVG4 aa: 243-253) from JPT is produced under strict quality control and quality management.
EBV EBNA4 243-253, RRARSLSAERY - Specifications
- Peptide sequence: H-RRARSLSAERY-OH
- Amount: 10 mg (10 x 1 mg)
- Purity: Trial Grade: each peptide purified to > 90% (HPLC/MS)
- Counterion: TFA
- Delivery Format: Freeze-dried in glass vial
- Application(s): T-cell Immunity
- Condition(s)/Topic(s): Infection
- Standard Delivery Time: approx. 3 weeks
JPT’s Antigen Peptides
Find your antigen peptide and select the connected PepMix™ Peptide Pool for efficient immune monitoring, mapping of T cell epitopes or development of immunotherapy and vaccines. JPT Peptide Technologies has substantial, long-standing expertise in providing peptides, peptidomimetics, and proteins to the global scientific community. Our highly skilled and committed scientific staff ensures that the most appropriate methods and techniques are selected for every synthesis project. All our catalog peptides are provided with HPLC-MS analyses to confirm the identity and demonstrate the high quality of our peptides.
Not found what you are looking for? Request a Quote for you custom antigen peptide!
Benefits of JPT’s Antigen Peptides
- All peptides are made in Germany
- Bulk orders or custom peptide snythesis upon request
- Synthesis protocols designed to avoid toxic contaminants and side products
- Provision of freeze dried aliquots for enhanced stability
- Proven track record for applications in clinical studies
- Order the connected PepMix™ Peptide Pool with your peptide!
References
References for EBV EBNA4 243-253, RRARSLSAERY
References:
Read References with JPT’s Antigen Peptides
EBV EBNA4 243-253, RRARSLSAERY has been described in:
Immunodominance among EBV-derived epitopes restricted by HLA-B27 does not correlate with epitope abundance in EBV-transformed B-lymphoblastoid cell lines., J Immunol, 2000 (PMID: 10843661)
HLA-B27 subtype polymorphism and CTL epitope choice: studies with EBV peptides link immunogenicity with stability of the B27:peptide complex., J Immunol, 1998 (PMID: 9820497)
MHC class I-associated peptides derive from selective regions of the human genome., J Clin Invest, 2016 (PMID: 27841757)
Documentation
Documentation for EBV EBNA4 243-253, RRARSLSAERY
Properties
Properties of EBV EBNA4 243-253, RRARSLSAERY
Properties | Values |
---|---|
Application: | T-cell immunity |
Category: | Antigen Peptides |
Condition / Topic: | Infection |
Layout: | Freeze-dried in glass vial |
Organism: | Epstein-Barr Virus (EBV) |
Protein Name: | Epstein-Barr nuclear antigen (EBNA) |
Purity: | Trial Grade: each peptide purified to > 90% (HPLC/MS) |
Quantification: | No, Yes |
Further Information to EBV EBNA4 243-253, RRARSLSAERY
Information | Values |
---|---|
Sequence: | H-RRARSLSAERY-OH |
Specifications: | 11mer peptide as TFA salt |